Press releases

 

June 2018 · Pluristem
Pluristem Reports Positive Top-Line Results from Its Multinational Phase II Intermittent Claudication Study
The IC study validates the design of our ongoing PACE phase III trial on Critical Limb Ischemia (CLI). Best results in the IC trial were obtain with two times administration of 300 million PLX-PAD cells. The same dosing is foreseen within PACE clinical study. Besides Pluristem, also other partners of the PACE consortium were involved in the IC trial as scientists: Sigrid Nikol (Asklepios) and Norbert Weiss (TUD) as lead principal investigator.
pdf download the article



February 2018 · Jerusalem Post · Sigrid Nikol
Smart cells that heal
Innovative Israeli cell therapy could step up treatment of CLI.
pdf download the article



February 2018 · LINC TODAY · Sigrid Nikol
Stem cell angiogenesis: showing promise
Pioneering techniques for critical limb ischaemia and "no option patients".
pdf download the article



July 2017 · Pluristem
Pluristem Advances its Multinational Phase III Critical Limb Ischemia Study, Targeting Initiation at 40 Active Sites
by the End of 2017
Austria’s regulatory health agency clears CLI study and joins the U.S., U.K., and Germany in conducting the 250-patient Phase III trial.
pdf download the article



January 2017 · Pluristem
Pluristem’s Phase III Study of PLX-PAD Cells for the Treatment of Critical Limb Ischemia Cleared by U.S. FDA
pdf download the article